Mingjiu Chen
Founder, Chairman & Chief Executive Officer Biosion
Seminars
Thursday 11th June 2026
Advancing Next-Generation Bispecific Antibodies: From Rigidity to Flexibility for Differentiation & Clinical Translation
12:00 pm
- Designing the strategy and target rationale of FlexiBody®, a multi-specific antibody platform
- Engineering considerations to optimize efficacy while mitigating on-target toxicity
- Exploring translational insights supporting clinical development and differentiation
